Bristol-Myers Squibb

Global biopharmaceutical business Bristol-Myers Squibb (BMS) is dedicated to finding, creating, and providing cutting-edge medications to treat people with life-threatening ... Global biopharmaceutical business Bristol-Myers Squibb (BMS) is dedicated to finding, creating, and providing cutting-edge medications to treat people with life-threatening illnesses. BMS, which has its headquarters in New York City, was established in 1858 by William McLaren Bristol and John Ripley Myers as a pharmaceutical manufacturing company in Clinton, New York. The company has a rich history that spans more than a century. Through mergers, acquisitions, and business alliances, the company has developed over time to rank among the top participants in the pharmaceutical sector.BMS is dedicated to promoting scientific understanding and enhancing patient outcomes in a variety of therapeutic domains, including as immunology, fibrosis, cardiovascular disease, and oncology. The pipeline of the company includes several chemicals that show promise in treating different types of ailments. demonstrating its commitment to meeting unmet medical needs and enhancing patients' lives all throughout the world.With ground-breaking treatments like Opdivo (nivolumab) and Yervoy (ipilimumab), which have completely changed the way that many cancers are treated, including melanoma, lung cancer, and renal cell carcinoma, BMS has achieved great progress in the field of oncology. Immune checkpoint inhibitors give patients with advanced or metastatic disease new hope by directing the body's immune system against cancer cells.In addition to cancer, BMS is actively engaged in the development of medicines for immunological conditions such as lupus and rheumatoid arthritis, as well as cardiovascular diseases such as heart failure and thrombosis. Additionally, the business is investigating cutting-edge methods for treating fibrotic disorders, which cause excessive tissue and organ scarring, which contributes to to ailments including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis.Apart from its concentration on drug discovery and development, BMS is dedicated to enhancing global health equity and healthcare accessibility. The company works to increase access to its medications through a variety of collaborations and activities, especially in underserved populations and resource-poor countries.All things considered, Bristol-Myers Squibb keeps pushing biopharmaceutical innovation by utilizing its scientific know-how, cooperative alliances, and worldwide reach to significantly improve patient outcomes and the state of healthcare overall.